|
|
Volumn 11, Issue 3, 2017, Pages 297-304
|
|
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
a a a a a a |
|
Author keywords
biosimilar; immunogenicity; Inflammatory bowel disease; infliximab; switching
|
|
Indexed keywords
ANTIBODY;
BIOSIMILAR AGENT;
C REACTIVE PROTEIN;
CALGRANULIN;
CT-P13;
HEMOGLOBIN;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
ADOLESCENT;
ADULT;
AGED;
BLOOD;
CHEMISTRY;
COLITIS, ULCERATIVE;
CROHN DISEASE;
DRUG SUBSTITUTION;
FEASIBILITY STUDY;
FECES;
FEMALE;
FOLLOW UP;
HUMAN;
IMMUNOLOGY;
MALE;
METABOLISM;
MIDDLE AGED;
PROSPECTIVE STUDY;
SEVERITY OF ILLNESS INDEX;
VERY ELDERLY;
YOUNG ADULT;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTIBODIES;
ANTIBODIES, MONOCLONAL;
BIOSIMILAR PHARMACEUTICALS;
C-REACTIVE PROTEIN;
COLITIS, ULCERATIVE;
CROHN DISEASE;
DRUG SUBSTITUTION;
FEASIBILITY STUDIES;
FECES;
FEMALE;
FOLLOW-UP STUDIES;
HEMOGLOBINS;
HUMANS;
INFLIXIMAB;
LEUKOCYTE L1 ANTIGEN COMPLEX;
MALE;
MIDDLE AGED;
PROSPECTIVE STUDIES;
SEVERITY OF ILLNESS INDEX;
YOUNG ADULT;
|
|
EID: 85021225235
PISSN: None
EISSN: 18764479
Source Type: Journal
DOI: 10.1093/ecco-jcc/jjw166 Document Type: Article |
|
Times cited : (82)
|
|
References (0)
|